💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Brimonidine Tartrate

CHEMBL1200389 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
442.2 g/mol
LogP
—
Phase
4

The tartrate salt of brimonidine, commonly formulated as ophthalmic drops to reduce elevated eye pressure in glaucoma. It works by decreasing fluid production inside the eye and enhancing uveoscleral outflow. It should be used with caution in young children due to the risk of central nervous system depression.

Peso Molecular

442,2200 g/mol

TPSA

177,00 Ų

Áreas Terapêuticas

Ovarian Cancer Glaucoma Age-Related Macular Degeneration Systemic Lupus Erythematosus Multiple Sclerosis Hypertension Prostate Cancer

Mecanismo de Ação

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)[C@H](O)[C@@H](O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H16BrN5O6

                    

                    
                    

                        
HBD / HBA

                        
6 / 9

                    

                    
                    

                        
Ligações Rotacionáveis

                        
5

                    

                    
                    
                    

                        
Átomos Pesados

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
The tartrate salt of brimonidine, commonly formulated as ophthalmic drops to reduce elevated eye pressure in glaucoma. It works by decreasing fluid production inside the eye and enhancing uveoscleral outflow. It should be used with caution in young children due to the risk of central nervous system depression.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Brimonidine Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200389.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 54405.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.